EA201490631A1 - Способы культивирования клеток млекопитающих для получения белка - Google Patents

Способы культивирования клеток млекопитающих для получения белка

Info

Publication number
EA201490631A1
EA201490631A1 EA201490631A EA201490631A EA201490631A1 EA 201490631 A1 EA201490631 A1 EA 201490631A1 EA 201490631 A EA201490631 A EA 201490631A EA 201490631 A EA201490631 A EA 201490631A EA 201490631 A1 EA201490631 A1 EA 201490631A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
mammalian cells
protein
cultivation
protein product
Prior art date
Application number
EA201490631A
Other languages
English (en)
Other versions
EA028491B1 (ru
Inventor
Ин Цзин
Чжэнцзянь Ли
Юэмин Цянь
Original Assignee
Бристол-Майерс Сквибб Кампани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43823459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201490631(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бристол-Майерс Сквибб Кампани filed Critical Бристол-Майерс Сквибб Кампани
Publication of EA201490631A1 publication Critical patent/EA201490631A1/ru
Publication of EA028491B1 publication Critical patent/EA028491B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение раскрывает методы и способы для получения белков, в частности гликопротеинов, с помощью культивирования клеток животных или клеток млекопитающих, предпочтительно, но не ограничиваясь ими, подпитываемых культур клеток. В одном аспекте способы включают добавление глюкокортикоидного соединения в процессе периода культивирования. Добавление глюкокортикоидного соединения поддерживает высокую жизнеспособность культивируемых клеток и может приносить повышенный конечный титр продукта белка и высококачественный продукт белка, что определяют, например, содержанием сиаловой кислоты получаемого белка.
EA201490631A 2009-10-06 2010-10-06 СПОСОБ КУЛЬТИВИРОВАНИЯ КЛЕТОК ДЛЯ ПОЛУЧЕНИЯ ГЛИКОЗИЛИРОВАННОЙ РЕКОМБИНАНТНОЙ МОЛЕКУЛЫ CTLA4Ig EA028491B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27834309P 2009-10-06 2009-10-06
US12/897,857 US9540426B2 (en) 2009-10-06 2010-10-05 Mammalian cell culture processes for protein production

Publications (2)

Publication Number Publication Date
EA201490631A1 true EA201490631A1 (ru) 2016-05-31
EA028491B1 EA028491B1 (ru) 2017-11-30

Family

ID=43823459

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201270469A EA025604B1 (ru) 2009-10-06 2010-10-06 СПОСОБ ПОЛУЧЕНИЯ ГЛИКОЗИЛИРОВАННОЙ РЕКОМБИНАНТНОЙ МОЛЕКУЛЫ CTLA4Ig
EA201490631A EA028491B1 (ru) 2009-10-06 2010-10-06 СПОСОБ КУЛЬТИВИРОВАНИЯ КЛЕТОК ДЛЯ ПОЛУЧЕНИЯ ГЛИКОЗИЛИРОВАННОЙ РЕКОМБИНАНТНОЙ МОЛЕКУЛЫ CTLA4Ig

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201270469A EA025604B1 (ru) 2009-10-06 2010-10-06 СПОСОБ ПОЛУЧЕНИЯ ГЛИКОЗИЛИРОВАННОЙ РЕКОМБИНАНТНОЙ МОЛЕКУЛЫ CTLA4Ig

Country Status (26)

Country Link
US (3) US9540426B2 (ru)
EP (1) EP2486048B2 (ru)
JP (1) JP2013506436A (ru)
KR (1) KR20120100973A (ru)
CN (1) CN102753572A (ru)
AR (1) AR078544A1 (ru)
AU (1) AU2010303590B2 (ru)
BR (1) BR112012007854A2 (ru)
CA (1) CA2777050C (ru)
CO (1) CO6531436A2 (ru)
CY (1) CY1118734T1 (ru)
DK (1) DK2486048T4 (ru)
EA (2) EA025604B1 (ru)
ES (1) ES2613269T5 (ru)
HR (1) HRP20170269T4 (ru)
HU (1) HUE031867T2 (ru)
IL (1) IL219124A (ru)
LT (1) LT2486048T (ru)
MX (1) MX2012003654A (ru)
PL (1) PL2486048T5 (ru)
PT (1) PT2486048T (ru)
RS (1) RS55727B2 (ru)
SI (2) SI2486048T1 (ru)
SM (1) SMT201700116B (ru)
TW (1) TW201118176A (ru)
WO (1) WO2011044180A1 (ru)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201510384UA (en) 2006-09-13 2016-01-28 Abbvie Inc Cell culture improvements
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TW201024318A (en) * 2008-10-20 2010-07-01 Abbott Lab Isolation and purification of antibodies using protein A affinity chromatography
EP2346897A2 (en) 2008-10-20 2011-07-27 Abbott Laboratories Viral inactivation during purification of antibodies
US9540426B2 (en) * 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CA2840951A1 (en) 2011-07-08 2013-01-17 Merck Sharp & Dohme Corp. Methods for purifying fc-fusion protein
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US20130281355A1 (en) * 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
CN109370980B (zh) 2012-05-02 2023-05-09 生命技术公司 高产量瞬时表达系统
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
EP2867251B1 (en) * 2012-06-29 2019-08-21 Bristol-Myers Squibb Company Methods for reducing glycoprotein aggregation
BR112015004467A2 (pt) 2012-09-02 2017-03-21 Abbvie Inc método para controlar a heterogeneidade de proteínas
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2943563A1 (en) * 2013-01-10 2015-11-18 Biogen MA Inc. Medium supplements for improved process performance
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
SG11201507875RA (en) 2013-03-26 2015-10-29 Coherus Biosciences Inc Protein production method
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
MX362923B (es) * 2014-01-30 2019-02-25 Coherus Biosciences Inc Medios de perfusión.
US11124760B2 (en) * 2014-03-24 2021-09-21 Biogen Ma Inc. Methods for overcoming glutamine deprivation during mammalian cell culture
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
EA038482B1 (ru) * 2014-10-21 2021-09-03 Геннова Биофармасьютикалз Лимитед СПОСОБ ОЧИСТКИ ДЛЯ ВЫДЕЛЕНИЯ И КОММЕРЧЕСКОГО ПРОИЗВОДСТВА РЕКОМБИНАНТНОЙ TNK-tPA (ТЕНЕКТЕПЛАЗЫ)
US11319359B2 (en) 2015-04-17 2022-05-03 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
CN106318998B (zh) * 2015-07-08 2019-08-20 浙江海正博锐生物制药有限公司 用于提高重组人ⅱ型肿瘤坏死因子受体-抗体融合蛋白唾液酸化水平的组合物
EP3322813A1 (en) * 2015-07-13 2018-05-23 Life Technologies Corporation System and method for improved transient protein expression in cho cells
KR20180073693A (ko) * 2015-11-09 2018-07-02 브리스톨-마이어스 스큅 컴퍼니 Cho 세포에서 생산되는 폴리펩티드의 품질 속성을 조작하는 방법
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CA3077509A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
CN108659095A (zh) * 2018-05-18 2018-10-16 上海药明生物技术有限公司 一种使唾液酸含量稳定的方法
CN114592005B (zh) * 2022-04-12 2023-12-19 厦门大学 一种糖皮质激素的检测方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357422A (en) * 1980-08-14 1982-11-02 Massachusetts Institute Of Technology Method of enhancing interferon production
EP0217822B1 (en) * 1985-02-13 1993-05-12 Scios Nova Inc. Human metallothionein-ii promoter in mammalian expression system
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US5264550A (en) * 1985-04-15 1993-11-23 Scios Nova Inc. Human anti-inflammatory phospholipase inhibitor protein
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
GB8924021D0 (en) 1989-10-25 1989-12-13 Celltech Ltd Recombinant dna method and vectors for the use therein
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6090914A (en) * 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
JP3722375B2 (ja) * 1991-06-27 2005-11-30 ブリストル−マイヤーズ スクイブ カンパニー Ｃｔｌａ４レセプター、それを含有する融合タンパク質およびそれらの使用
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5773253A (en) * 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
JPH08308561A (ja) * 1995-05-16 1996-11-26 Sumitomo Electric Ind Ltd 動物細胞培養用無血清培地
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
JP4306813B2 (ja) * 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
AU1003001A (en) 1997-01-31 2001-04-12 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
WO1999061650A1 (en) 1998-05-29 1999-12-02 Genentech, Inc. Cell culture process for producing glycoproteins
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
IL145893A0 (en) 1999-04-26 2002-07-25 Genentech Inc Cell culture process for glycoproteins
US6261805B1 (en) * 1999-07-15 2001-07-17 Boyce Thompson Institute For Plant Research, Inc. Sialyiation of N-linked glycoproteins in the baculovirus expression vector system
JP4443714B2 (ja) 2000-03-28 2010-03-31 明治乳業株式会社 細胞培養におけるｂ型肝炎ウイルス表面抗原の高収率生産方法
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
ATE271066T1 (de) * 2000-05-26 2004-07-15 Bristol Myers Squibb Co Lösliche mutante ctla4 moleküle und deren verwendung
AU2003303394B2 (en) 2002-12-23 2009-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
WO2004058800A2 (en) 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US10508144B2 (en) * 2005-12-20 2019-12-17 Bristol-Myers Squibb Company Carbohydrate content of CTLA4 molecules
US9540426B2 (en) * 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US8678606B2 (en) 2010-06-14 2014-03-25 Aja Berger Carrying container with at least two light sources

Also Published As

Publication number Publication date
AR078544A1 (es) 2011-11-16
US10059754B2 (en) 2018-08-28
PL2486048T3 (pl) 2017-07-31
RS55727B2 (sr) 2020-09-30
JP2013506436A (ja) 2013-02-28
US20170129937A1 (en) 2017-05-11
TW201118176A (en) 2011-06-01
WO2011044180A1 (en) 2011-04-14
EA025604B1 (ru) 2017-01-30
CN102753572A (zh) 2012-10-24
BR112012007854A2 (pt) 2016-11-22
DK2486048T4 (da) 2020-03-30
DK2486048T3 (en) 2017-02-27
PT2486048T (pt) 2017-02-06
EA028491B1 (ru) 2017-11-30
CY1118734T1 (el) 2017-07-12
CO6531436A2 (es) 2012-09-28
HRP20170269T1 (hr) 2017-04-07
ES2613269T3 (es) 2017-05-23
HRP20170269T4 (hr) 2020-04-03
SMT201700116B (it) 2017-03-08
SI2486048T1 (sl) 2017-02-28
ES2613269T5 (es) 2020-08-03
US20110081679A1 (en) 2011-04-07
EA201270469A1 (ru) 2012-10-30
KR20120100973A (ko) 2012-09-12
US20170129936A1 (en) 2017-05-11
EP2486048A1 (en) 2012-08-15
US9540426B2 (en) 2017-01-10
HUE031867T2 (en) 2017-09-28
AU2010303590A1 (en) 2012-05-03
EP2486048B1 (en) 2016-11-23
IL219124A0 (en) 2012-06-28
IL219124A (en) 2017-10-31
US10030064B2 (en) 2018-07-24
RS55727B1 (sr) 2017-07-31
MX2012003654A (es) 2012-04-30
AU2010303590B2 (en) 2016-07-07
PL2486048T5 (pl) 2020-07-13
LT2486048T (lt) 2017-02-10
CA2777050C (en) 2016-12-20
CA2777050A1 (en) 2011-04-14
SI2486048T2 (sl) 2020-04-30
EP2486048B2 (en) 2019-12-25

Similar Documents

Publication Publication Date Title
EA201270469A1 (ru) Способы культивирования клеток млекопитающих для получения белка
WO2011091350A3 (en) Methods & compositions for improving protein production
EA201991976A1 (ru) Метаболически оптимизированная клеточная культура
EA200501774A1 (ru) Культуры e1-иммортализованных клеток и способы их культивирования с целью повышения выхода их продукции
EP4148121A3 (en) Cell-controlled perfusion in continuous culture
CY1118863T1 (el) Καλλιεργεια κυτταρου θηλαστικου
WO2004058800A3 (en) Mammalian cell culture processes for protein production
ATE488600T1 (de) Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
BR112012027430A2 (pt) processo de cultivo de células aprimorado
BR112022013569A2 (pt) Construções de célula viva para produção de produto lácteo cultivado e métodos usando as mesmas
MY156588A (en) Systems using cell culture for production of isoprene
EA201171018A1 (ru) Биореактор для культивирования клеток млекопитающих
MX2012001742A (es) Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
EA201270213A1 (ru) Способ получения полипептида или вируса, представляющих интерес, в непрерывной клеточной культуре
WO2011075686A3 (en) Methods & compositions comprising heat shock proteins
WO2012031263A3 (en) Cell culture system for bioreactor scale-up of cells
EA201590550A1 (ru) Композиции и способы получения гликопротеинов
PH12014502870A1 (en) Method of producing recombinant iduronate-2-sulfatase
WO2010068897A3 (en) Stem cell enhanced protein products and uses thereof
AR086200A1 (es) Hongos filamentosos que tienen un fenotipo de viscosidad alterado
EA201170025A1 (ru) Способы повышения жизнеспособности и продукции культуры клеток
CA2796599A1 (en) Method for producing induced pluripotent stem cells
EA200900984A1 (ru) Улучшение клеточного роста
EA201301163A1 (ru) Высокоэффективный способ ферментации
WO2013032999A3 (en) Polydnavirus vectors

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM